• Antibodies to HHV-6 during acute COVID-19 may help predict development of Long COVID

    Autoantibodies directed against neural targets have most predictive power.

  • iciHHV-6B linked to systemic lupus erythematosus (SLE) in Japanese and European populations

    iciHHV-6B, when integrated into chromosome 22q, was strongly associated with SLE and with SLE severity.

  • HHV-6 linked to miscarriage through Mendelian randomization studies

    The findings are consistent with previous studies directly linking HHV-6 endometrial infection to miscarriage.

  • Finnish investigators find unexpected evidence of HHV-6B integration into mitochondrial DNA

    Could HHV-6B infection exacerbate mitochondrial disease?

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Immunity & Immunotherapy Articles

View Post

HHV-6B Ribonucleotide Reductase Sequesters NF-κB Subunit p65 to Inhibit Innate Immune Responses

In All, Genes, Immunity & Immunotherapy by Kristin LoomisApril 28, 2025

This study helps explain how roseoloviruses maintain persistent infection.

View Post

New mechanism identified by which HHV-6B evades NK cell recognition

In All, Genes, Immunity & Immunotherapy by Kristin LoomisJuly 29, 2024

HHV-6B U20 protein inhibits NK cell attacks on virally-infected cells.

View Post

Part 1: Latent HHV-6 is reactivated in patients receiving CAR-T cell therapy

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisApril 18, 2024

Investigators urge careful monitoring for HHV-6 and ciHHV-6.

View Post

Part 2: CAR-T cell therapy and its complications

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?

View Post

Part 3. HHV-6 Encephalitis in CAR-T Cell therapy

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.

View Post

Part 4. Might HHV-6 contribute to some cases of cytokine release syndrome, pneumonia, and cytopenias in CAR-T Cell therapy?

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

While unlikely to trigger the cytokine storm, HHV-6 infection may perpetuate it, and contribute directly to cytopenias and pneumonia.

View Post

Early HHV-6 specific T-cell responses by ELISpot were remarkably higher in alloHSCT patients who went on to develop clinically relevant infections

In All, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisOctober 31, 2023

T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts.

View Post

Adding an adoptive NK cell infusion to naïve T-Cell-depleted grafts may reduce the rate of HHV-6B reactivation and encephalitis

In All, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisAugust 15, 2022

A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.

View Post

Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients

In All, Hematological Disorders, Immunity & Immunotherapy by Kristin LoomisJune 16, 2022

HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients

View Post

The effects of HHV-6B infection on immune checkpoint inhibition

In All, Hematological Disorders, Immune Dysfunction, Immunity & Immunotherapy, Latest Scientific News by Kristin LoomisMay 20, 2022

HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways

View Post

HHV-6 linked to intrauterine growth restriction via the human leukocyte antigen-G dysregulation

In All, Immunity & Immunotherapy, Latest Scientific News by Kristin LoomisJanuary 3, 2022

A small study found a strong association between HHV-6 infection of the placenta and intrauterine growth restriction—a finding consistent with other evidence linking HHV-6 to several reproductive diseases.

View Post

HHV-6A and 7 infection of T cells downregulates the protein tyrosine phosphatase, CD45

In All, Immunity & Immunotherapy, Latest Scientific News by Kristin LoomisJanuary 3, 2022

CD45, important in T cell receptor signaling, may be one mechanism by which roseolaviruses evade immune detection and help achieve latency

View Post

iciHHV-6 may modulate human gene expression

In All, ciHHV-6, Genes, Immunity & Immunotherapy by Kristin LoomisJune 2, 2020

A Japanese group found that ciHHV6 genes encoding for immunoglobulins were decreased in ciHHV6 individuals, possibly modulating immune responses.

View Post

HHV-6A, HHV-6B, and HHV-7 have differential impact on intracellular DNA sensors of NK cells

In All, Immunity & Immunotherapy, Latest Scientific News by Kristin LoomisJune 2, 2020

Cytokine and chemokine responses were very similar in HHV-6B and HHV-7 infections. The results were starkly different for HHV-6A.

View Post

49 new CD4 T-cell-recognized HHV-6B antigens identified using genome-wide approach

In All, Immunity & Immunotherapy by Kristin LoomisJune 3, 2019

University of Washington investigators utilized rare cell enrichment and an HLA-agnostic, proteome-wide approach to expand the library of known HHV-6 T cell antigens from 11 to 60.

  • Page 1 of 2
  • 1
  • 2
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use